Core Viewpoint - The stock of Baixinan-B (02185) experienced significant volatility, with a peak increase of over 15% and a closing rise of more than 50% recently, indicating strong market interest and potential investor confidence in the company [1]. Group 1: Market Reaction - Baixinan-B's stock price rose by 11.4% to HKD 10.36, with a trading volume of HKD 42.644 million [1]. Group 2: Industry Developments - The American Heart Association (AHA) and the American College of Cardiology (ACC) released updated guidelines for the prevention, detection, assessment, and management of adult hypertension, marking significant revisions from the 2017 guidelines [1]. - The new guidelines include updates on the diagnosis, risk assessment, and treatment of hypertension, aiming to provide more precise clinical guidance to reduce cardiovascular disease (CVD) risk [1]. - Renal denervation (RDN) has been added as a recommended treatment option in the updated guidelines [1]. Group 3: Regulatory Changes - The Centers for Medicare & Medicaid Services (CMS) proposed a new RDN insurance coverage plan for patients with uncontrolled hypertension, which is currently in a 30-day public comment period [1]. - The final decision on the new RDN insurance proposal is expected to be announced by October 8, 2025, or earlier [1].
百心安-B一度涨超15% 昨日收涨逾50% RDN进入美国高血压指南